Therapeutic inhibition of HBsAg and HBV cccDNA through a novel phased combination treatment: glycine and interferon-α

Glycine has the potential to reduce HBV cccDNA levels by stimulating hepatocyte proliferation. The phased administration of glycine and IFN-α significantly enhances its therapeutic efficacy. These findings suggest a novel and promising strategy for the treatment of CHB.